SGLT2 Inhibitors Lowers Gout Risks in Type 2 Diabetes A population-based cohort has demonstrated tha SGLT2i use in gout patients is superior to sulfonylurea therapy in lowering the risk of incident gout and recurrent flares among patients withT2D. https://t.co/QZ7bt39zEW https://t.co/Wlo9SF0hPF